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Abstract 
Right ventricular outflow tract (RVOT) and pulmonary valve dysfunction account for 
roughly 20% of all congenital heart diseases. Over time, these types of dysfunction can lead to 
right heart failure, which is associated with significant morbidity and mortality. Improvements in 
RVOT and pulmonary valve function may reverse some of the deleterious effects. Historically, 
surgical pulmonary valve replacement has been the mainstay method of pulmonary valve repair. 
In 2010, percutaneous pulmonary valve implantation (PPVI) was introduced in the US. This study 
analyzed the healthcare costs for 47 and 51 patients that underwent PPVI and surgical pulmonary 
repair, respectively, at Yale-New Haven Hospital from 2007 to 2014. The analysis included all 
costs incurred during the hospital admission and follow-up visits within one month of discharge. 
The overall total PPVI and surgery costs were $71,966 ± 16,326 and $90,917 ± 22,639, 
respectively (p < 0.001). The difference of $18,951 is largely accounted for by the difference in 
indirect costs, $24,553 ± 7,018 and $36,195 ± 15,735 (p < 0.001). The remaining difference can 
be attributed to the direct costs, which were broken down by department. Surgery was more costly 
in nearly all categories, including physician fees, ICU care, and non-ICU care. The only exception 
was that the PPVI valve ($26,154) cost 3.5 times as much as the surgical valve ($7,556).  
A multivariate regression analyses of the overall total cost with patient demographic and 
clinical characteristics yielded a model consisting of the variable, hospital length of stay, as the 
only statistically significant predictor of cost (p = 0.016, R2  =  0.363).  
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Introduction 
Right Ventricular Outflow Tract Dysfunction  
The prevalence of congenital heart disease ranges from 6 to 13 out of 1000 live births (1). 
Of all congenital heart diseases, roughly 20% involve right ventricular outflow tract (RVOT) and 
pulmonary valve dysfunction (2). These defects are present in pathologies including 
transposition of the great arteries, tetralogy of Fallot, truncus arteriosus, double outlet right 
ventricle, and others. While surgical techniques exist to modify and improve RVOT and 
pulmonary valve dysfunction, these methods in general do not result in complete normalization 
of the RVOT or pulmonary valve function. Thus, patients with these types of congenital heart 
disease frequently endure life-long RVOT and valve dysfunction to varying degrees.  
Both RVOT and pulmonary valve dysfunction can eventually lead to right heart failure. 
RVOT obstruction results in pressure overload of the right ventricle with resultant muscular 
hypertrophy, which itself has deleterious effects on systolic and diastolic function. Pulmonary 
valve regurgitation results in volume overload of the right ventricle. This often leads to 
progressive chamber dilation with associated tricuspid valve regurgitation and systolic 
dysfunction. 
Studies indicate that severe RVOT dysfunction and pulmonary regurgitation can lead to 
increased morbidity, such as exercise intolerance, atrial and ventricular arrhythmias, and 
increased overall mortality (3). Improvements in RVOT and pulmonary valve function may 
reverse some of the deleterious effects imposed by long-standing dysfunction and thereby 
decrease morbidity and mortality.  
There are currently two pulmonary valve repair methods: surgical pulmonary valve 
replacement and percutaneous pulmonary valve implantation (PPVI).  
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Surgical Pulmonary Valve Replacement and Percutaneous Pulmonary Valve 
Implantation 
In the 1950s, the development of open-heart surgery allowed congenital heart diseases to 
be treated with surgical techniques, which remained the standard treatment for RVOT and 
pulmonary valve defects for decades. Surgical repair involves the placement of a conduit, a 
segment of animal jugular vein containing a three-leaf valve, to connect the right ventricle to the 
pulmonary valve; in other instances, a patch to modify the patients’ own conduit is sufficient to 
repair the defect. Conduit replacement or reconstruction typically uses synthetic, homograft, or 
autograft tissue, which cannot grow with the host patient. Given the nature of congenital heart 
diseases that may necessitate surgery in the first days or months of life, patients may require 
repeat surgeries when they outgrow their prosthetic conduit. With time, RVOT obstruction and 
pulmonary regurgitation can also recur as the conduit and valve wear out. There is debate 
regarding the timing of repeat interventions: early intervention in the worsening disease process 
improves symptoms but would require more frequent re-intervention; later intervention may lead 
to irreversible deterioration of right ventricular function. Thus, the benefits of improving or 
maintaining ventricular function must be weighed against the risks and costs of repeat surgeries 
(4). 
In the late 1990s, the first transcatheter pulmonary valve was developed and successfully 
implanted into animals. In 2000, the first human transcatheter pulmonary valve replacement was 
performed on a 12-year old boy with stenosis and insufficiency of his prosthetic conduit (5). 
Transcatheter procedures created the possibility of providing the same, or similar, benefits to 
ventricular function as surgical replacement did - but without the risks of repeat sternotomies (4).  
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Further research and commercial development of the transcatheter pulmonary valve was 
conducted by Medtronic, Inc. Between 2006 and 2010, the Melody® valve was approved for use 
in the Europe, Canada, and United States. Since 2000, more than 6000 valves have been 
implanted and a dozen studies of early and mid-term outcomes conducted (3). These studies 
suggest that PPVI improves RVOT obstruction and regurgitation to reestablish ventricular load 
within normal range, while sustaining pulmonary valve competence. 
Research indicates that percutaneous pulmonary valve implantation (PPVI) is a 
promising alternative to surgery, providing similar benefits with less procedural morbidity. 
Statistically, roughly 50% of surgical conduits require replacement after 10 years, with 
subsequent replacements often having shorter lifespans (3).  
Melody® Valve and Its Clinical Use 
 
 
Figure 1. Melody® valve and Ensemble® transcatheter delivery system (3). 
The Melody® valve is composed of a valved bovine jugular venous conduit sutured into 
a balloon expandable metal stent. At its smallest, the flexible stent can be crimped into a 
diameter of 7mm. On inflation, the valve can function well from a diameter of 14mm to 22mm; 
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flexibility and wide range in size were important in the design of this valve, due to the variability 
in RVOT architecture that different patients may have (4).  
The Ensemble® transcatheter delivery system consists of a guide wire and two balloons 
that facilitate conduit deployment. The delivery system is inserted through the femoral vein into 
the RVOT. The balloons are then inflated sequentially to deploy the valve. Once the valve is 
implanted, the balloons are deflated, and the delivery system is removed (4).  
The Melody® valve was approved by the FDA under the Humanitarian Device 
Exemption Program for use as an adjunct therapy to surgery. Guidelines dictate that the adult or 
pediatric patient must have a RVOT of at least 16mm in diameter, with RVOT dysfunction that 
requires intervention: either moderate to severe regurgitation or stenosis (mean RVOT pressure 
gradient ≥ 35mm) (4). 
Economic Analyses in Healthcare 
Rising healthcare spending in the US has brought increasing scrutiny to its high costs. As 
such, economic analyses of healthcare services have become increasing relevant and important to 
many stakeholders, including patients, physicians, administrators, taxpayers, and policymakers. 
Results of these analyses may have a significant impact on healthcare policy: for example, when 
presented with multiple options, lawmakers may choose to fund the interventions that are more 
cost-effective over others. This section provides a brief overview of the main types of economic 
analyses and their key attributes. 
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Table 1. Types of economic analyses (6). 
Analysis Type Metric Description 
Cost analysis $ Evaluates only cost of an intervention. 
Cost-effectiveness 
analysis 
$/year 
Evaluates cost per additional year of life gained 
due to an intervention. 
Cost-utility analysis 
$/QALY* or 
$/DALY** 
Evaluates cost per additional year of life of 
equivalent quality gained due to an intervention. 
Cost benefit 
analysis 
Variable metric 
Evaluates all positive and negative consequences 
of an intervention, converted to a comparable 
metric. Typically used to evaluate effects of public 
policies. 
*Quality-adjusted life-year. **Disability-adjusted life-year. 
Cost analyses evaluate cost only, without regard to the effectiveness of the intervention. 
Cost-effectiveness, cost-utility, and cost benefit analyses can only be conducted if the 
effectiveness of the intervention is well-understood and quantifiable. 
When calculating costs, it is important to consider the perspective of the analyses.  
Table 2. Perspectives of cost analyses. 
Perspective Description 
Patient / family Costs borne by patient and family. 
Provider Costs borne by hospitals, clinics, etc. 
Payer Costs borne by insurance companies, Medicaid, Medicare, etc. 
Health system 
Costs related to providing health care, including all categories of 
providers. 
Society All costs, regardless of who bears them. 
Other important attributes of economic analyses include types of cost, time horizon, 
discounting and inflation (7): 
Types of cost: direct healthcare costs include physician services, hospital services, 
medications, etc. Direct non-healthcare costs are those incurred surrounding healthcare, such as 
transportation to and from care facilities. Indirect costs include healthcare administration, 
finance, utilities, etc.  
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Time horizon: this refers to the time frame within which significant health and economic 
outcomes are captured in the analysis. Depending on the intervention, the time horizon may 
range from a single disease episode, one patient lifetime, or even multiple generations. 
Discounting: discounting accounts for the passage of time and preference for benefits to 
occur earlier rather than later. This is because costs and benefits that occur in the future are 
considered to have less value than those that occur today.  
Inflation: given that ten years ago, $1 had greater purchasing power than it does today, 
costs from different years must be adjusted for inflation so that all values are in dollars of one 
single comparable year.  
Published Cost Analyses of Transcatheter Valvular Procedures 
Cost analyses of transcatheter valvular procedures have primarily focused on aortic and 
mitral valve implantations in adults. Due to the immaturity of the field of mitral valve 
implantation and its research, only the cost studies on aortic valve replacement are discussed 
here. 
Transcatheter aortic valve replacement (TAVR) is approved to treat symptomatic aortic 
stenosis in patients unsuitable or at high risk for surgical correction. Without treatment, 
symptomatic aortic stenosis has a mean survival duration of only 1.8 years and a high 5-year 
mortality rate of 88% (8). Since its first use in 2002, more than 100,000 procedures have been 
performed around the world (9). It is estimated that the prevalence of severe aortic stenosis is 
3.4% in the elderly (>75 years old), accounting for 27,000 new TAVR candidates in Europe and 
North America annually (10).  
Given the significant patient population and relatively longer history of TAVR 
(compared to PPVI), studies have focused on two issues: cost effectiveness of TAVR versus 
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medical therapy in nonsurgical candidates, and cost effectiveness of TAVR versus surgical aortic 
valve replacement (SAVR). Two cost studies were based on the randomized controlled clinical 
study, Placement of Aortic Transcatheter Valves (PARTNER) trial. In cohort A, high risk 
patients were randomized to TAVR and SAVR. In cohort B, nonsurgical patients were 
randomized to TAVR and medical management. 
Cost comparisons of TAVR versus SAVR in high-risk patients have yielded inconsistent 
results. One was based on a randomized controlled trial, and the others were based on 
hypothetical patient population models. Among the six studies across North America and 
Europe, half found TAVR to be more cost-effective than SAVR. When TAVR was found to be 
more cost-effective, it was due to shorter hospital lengths of stay and/or decreased follow-up 
medical costs (11, 12). When TAVR was less cost-effective, it was attributed to the significantly 
higher cost of the TAVR valve (11, 13, 14).  Three of the studies differentiated between 
transapical (TA) and transfemoral (TF) TAVR, because the different access sites are thought to 
affect procedural risk and recovery. The studies concluded that TF-TAVR was more cost-
effective than SAVR, but TA-TAVR was less cost-effective than SAVR (11, 13, 15).  
Table 3. Cost-effectiveness studies comparing TAVR and SAVR in high-risk patients (8). 
Authors Location Study Method Time Horizon Result 
Reynolds et al. US Based on PARTNER trial. 1 year TF1 >3 SAVR 
    SAVR > TA2  
Gada et al. US 
Hypothetical patient population 
model. TF vs. SAVR. 
Lifetime TF > SAVR 
Gada et al. US 
Hypothetical patient population 
model. TA vs. SAVR. 
Lifetime SAVR > TA 
Doble et al. Canada 
Hypothetical patient population 
model.  
20 years SAVR > TAVR  
Neyt et al. Belgium 
Hypothetical patient population 
model.  
1 year SAVR > TAVR 
Fairbairn et al. UK 
Hypothetical patient population 
model. 
10 years TAVR > SAVR 
1TF transfemoral TAVR. 2TA transapical TAVR. 3 x > y indicates x is more cost-effective than y.  
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The only cost analysis based on the randomized controlled trial PARTNERS was 
conducted by Reynolds et al. In cohort A of the PARTNERS trial, high risk patients 
anatomically suitable for transfemoral access (n = 492) were randomized to TF-TAVR or SAVR. 
Those that were not suitable (n = 207) were randomized to TA-TAVR or SAVR. The trial found 
that TAVR or SAVR had similar 1- and 2-year survival rates. Quality of life was greater in 
TAVR patients at 1 month after the procedure, but similar at 6- and 12-month follow-up (16).  
Reynolds et al. also broke down the cost analysis by access site, but limited the analysis 
to the first 12 months, rather than lifetime time horizon (11). Of note, they assumed physician 
fees for TAVR and SAVR were identical; in contrast, the costs of the TAVR and SAVR valves 
were $5,277 and $30,000, respectively. TF-TAVR and SAVR had similar admission costs 
($73,219 vs. $74,067), because the higher valve cost was offset by shorter hospital stay (6 days). 
TA-TAVR patients similarly had shorter hospital stays (1-2 days), but it was insufficient to 
offset the higher valve cost and resulting overall admission cost ($90,919 vs. $79,024). Follow-
up costs were nearly identical for all groups. TAVR and SAVR cohorts as a whole were similar 
in cost-effectiveness; however, when the TAVR cohort was broken down by access site, TF-
TAVR was found to be more cost-effective than SAVR, while TA-TAVR was less cost-
effective. 
The seven cost studies comparing TAVR and medical therapy in nonsurgical candidates 
have been fairly consistent: all but one concluded that TAVR significantly increases survival, as 
well as healthcare costs. While TAVR may not be more cost-effective than medical 
management, the increased survival renders TAVR cost-effective. The studies were conducted in 
Europe and North America, with cost projections based on time horizons ranging from 3 year to 
lifetime. One was based on patient data from a randomized controlled trial; the remaining are 
14 
 
based on hypothetical patient populations with projected medical outcomes based on published 
literature and standardized medical costs within that country. The cost per quality-adjusted life-
year ranged widely, from $25,000 in the UK, to four times that amount in the US (8).  
Table 4. Cost-effectiveness studies comparing TAVR and medical therapy in nonsurgical 
candidates (8). 
Authors Location Study Method Time Horizon Result 
Reynolds et al. US Based on PARTNER trial. Lifetime TAVR >1 MM2 
Gada et al. US 
Hypothetical patient population 
model.  
Lifetime TAVR > MM 
Doble et al. Canada 
Hypothetical patient population 
model.  
20 years MM > TAVR 
Neyt et al. Belgium 
Hypothetical patient population 
model.  
Lifetime TAVR > MM 
Watt et al. UK 
Hypothetical patient population 
model.  
10 years TAVR > MM 
Hancock et al. Canada 
Hypothetical patient population 
model.  
3 years TAVR > MM 
Simon et al. US 
Hypothetical patient population 
model. 
Lifetime TAVR > MM 
1 x > y indicates x is more cost-effective than y.  
2 MM medical management. 
The cost study conducted by Reynolds et al. is considered to be the most definitive, 
because it is the only one based on data from the PARTNER randomized controlled clinical trial. 
Cohort B of the trial randomized nonsurgical patients with severe aortic stenosis to TAVR (n = 
179) or medical treatment (n = 179) in 21 centers (17 US, 3 Canadian, 1 European) (17). 
Reynolds et al. used medical and hospital billing data from the first 12 months after the 
procedure to project cost-effectiveness over the patient lifetime. Quality-adjusted life-years were 
derived by administering health status questionnaires at 1, 6, and 12 months (18). 
Compared to patients undergoing medical treatment, TAVR patients had lower 12-month 
follow-up costs ($29,289 versus $53,621) due to lower hospitalization rates. However, TAVR 
increased life expectancy by 1.6 years (1.3 quality-adjusted life-years), so the associated medical 
follow-up resulted in an incremental cost of $79,837. This translates to an incremental cost-
15 
 
effectiveness ratio of $50,200 per year of life gained, or $61,889 per quality-adjusted life-year 
gained. Given that the accepted incremental cost-effectiveness ratio in Western countries is 
typically taken to be $50,000 per quality-adjusted life-year gained, the authors concluded that 
TAVR is a cost-effective option for nonsurgical candidates (18).  
PPVI Cost Analyses 
Unlike aortic valve replacement studies, economic analyses of pulmonary valve 
replacement is limited to cost analyses only. This is because cost-effectiveness can only be 
evaluated when there is sufficient data on the effectiveness of an intervention, which is not yet 
available for PPVI due to its recent introduction and relatively small patient population.  
Table 5. Cost analyses of PPVI versus surgical replacement. 
Authors Location Study Method Time Horizon Result 
Gatlin et al. US 
Based on clinical data of 39 
patients. 
5 years PPVI >1 SM2 
Vergales et al. US 
Based on clinical data of 34 
patients. 
5, 10 years SM > PPVI 
Raikou et al. Canada 
Hypothetical patient population 
model.  
25 years PPVI > SM 
1 x > y indicates x costs more than y.  
2 SM surgical management. 
The first study comparing the costs of PPVI versus surgical pulmonary valve replacement 
was conducted at the Children’s Healthcare of Atlanta in 2011. The cohort included 33 surgical 
and 6 PPVI patients, who underwent procedures between 2004 and 2010. The study calculated 
the total 5-year hospital cost: this included direct hospital costs and labor costs; nurse and other 
ancillary personnel costs were estimated from hourly wages, and physician fees were estimated 
from Medicare reimbursement rates. The 5-year cost also included reintervention costs: the 
freedom from reintervention rates were derived from data published in three reintervention 
studies (53% for percutaneous pulmonary valves and 90% for surgical conduits), and the cost of 
each additional intervention was assumed to be the same as that of the first procedure (19).  
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While the cost of the transcatheter valve and delivery system ($30,500) was greater than 
that of the surgical conduit ($8,700), the total procedural costs were nearly identical ($50,000 per 
procedure). Due to the higher rate of reintervention for transcatheter valves, the study concluded 
a cost savings for surgical cases of $20,000 per patient at 5 years. However, the study 
acknowledges that the high cost of transcatheter pulmonary valves may be associated with the 
initial learning curve of the new technology; reintervention rates, and therefore total cost, may 
decrease in the future as experience with the device increases. Finally, the study recommends 
future analysis of costs to society: given that patients undergoing transcatheter procedures 
typically have hospital stays that are two days shorter than those undergoing surgery, the cost to 
families due to lost wages during the recovery period should be considered as well (19). 
A similar study was conducted in 2013 at the University of Virginia. The first 17 patients 
who had undergone PPVI were compared to 17 patients who had undergone surgery during the 
same time period. Both 5-year and 10-year economic estimates were made. Instead of costs, 
however, the data on actual hospital charges were obtained, then converted to hospital costs 
using a standard overall ratio of cost to charge specific to each department. Similar to the first 
study, charges and costs included only those associated with the admission for the procedure, and 
not those before or after discharge. Societal costs were also accounted for: wage loss was 
calculated by summing the patient’s hospital length of stay with recommended recovery time 
before returning to work. Wages were based on average, gender-specific earnings reported by the 
U.S. Department of Labor and U.S. Bureau of Labor Statistics. It was assumed that the mothers 
of patients under the age of 18 were out of work for the recommended patient recovery time. The 
authors also conducted a sensitivity analysis to model the degree to which the reintervention 
charges of the two procedures would need to change in order to result in equivalent costs (20). 
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The study found that the mean hospital charges for surgery patients ($126,406 + $38,772) 
were significantly higher than those for PPVI patients ($80,328 + $17,387), which is largely due 
to shorter length of stay (1 day + 0 vs. 5.7 + 2.2 days) without use of intensive care services. 
Furthermore, cost to society was lower for transcatheter patients due to shorter length of stay and 
recovery time, which resulted in wage loses of $611 versus $3,113. Sensitivity analyses showed 
that transcatheter implantation failure rates would need to be 17% per year, significantly higher 
than the published revision rate of 6%, before it lost its cost benefit. Thus, the authors concluded 
that transcatheter procedures have a clear cost advantage over surgical procedures (20). 
Outside the United States, a British study drew opposite conclusions. The study 
conducted at the Great Ormond Street Hospital in London compared the cost of treating patients 
with right ventricular outflow tract dysfunction when PPVI is available, and the cost of treating 
patients when only surgical replacement is available. There are several important differences 
between this and the American studies: first, the authors here excluded the first 50 PPVI patients 
to omit the effect of the learning curve; this resulted in 141 patients who had undergone PPVI. 
Second, the study used the average costs of these patients to project 25-year costs for a 
hypothetical population of 1,000 patients. In the study group with only surgery as a treatment 
option, the model assumes that a certain proportion of this group will undergo surgical re-
operation, another proportion will die, and the remaining proportion will be free of re-operation. 
In the cohort with PPVI as an option, a proportion will receive a second PPVI, another 
proportion will undergo surgical replacement, a third proportion will die, and the remaining will 
not need another procedure. The study concluded that PPVI is more costly than surgical 
management over 25 years, by £2,041 ($3,076) to £3,913 ($5,894) (21). 
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Study Methodology 
This study analyzed the clinical and financial records of PPVI patients and a comparable 
cohort of surgical patients who have undergone pulmonary valve replacement or implantation at 
Yale-New Haven Hospital between 2007 and 2014. 
PPVI Patients 
PPVI patients were identified from existing clinical databases. All patients who were 
reported to have undergone transcatheter pulmonary valve implantation at Yale-New Haven 
Hospital were included in the initial cohort. Additional clinical data were obtained through the 
Improving Pediatric and Adult Congenital Treatment (IMPACT) Registry. The initial group 
included 52 patients. One patient was excluded, because she had a Sapien, rather than Melody 
valve implant. Two patients were excluded, because PPVI was attempted but unsuccessful due to 
technical reasons, and surgical replacement was performed instead. One patient was excluded, 
because the Melody placement was part of a staged procedure with subsequent surgical tricuspid 
valve replacement during same admission. One patient was excluded, because the indication for 
PPVI was endocarditis. The remaining 47 patients, all of whom received Melody valves, were 
analyzed in this study.  
Surgical Patients  
The initial cohort of surgical patients was obtained from querying the surgical database of 
the Society of Thoracic Surgeons (STS) for all patients who had undergone pulmonary valve 
replacement at Yale-New Haven Hospital between January 1 2007 and December 31st, 2014 
(Figure 2). Additional clinical information was obtained through electronic medical records. The 
query returned 124 patients: 59 were excluded for weighing less than 15kg, the lower bound of 
patients eligible for PPVI. Six patients were excluded, because their right ventricular outflow 
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tracks were too large or too small. One patient was excluded, because the indication for 
pulmonary valve replacement was endocarditis. Seven patients were excluded for having 
additional concurrent procedures performed. The remaining surgical cohort analyzed in this 
study included 51 patients.  
Figure 2: Surgical cohort selection 
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Financial Records 
Hospital cost data were obtained from the Yale-New Haven Hospital Department of 
Analytic Strategy and Financial Planning. The data included itemized direct medical costs 
(excluding physician fees) for each patient’s hospital admission, indirect costs (administration, 
medical records, finance, utilities, etc.), and costs of outpatient and inpatient follow-up visits 
within one month after admission. Actual physician fees for each procedure were not able to be 
obtained from Yale Medical Group. Instead, physician fees were derived from current procedural 
terminology codes and standard Medicare reimbursement rates: $8,500 for PPVI and $11,040 for 
surgical replacement.  
Methods of Analysis 
The baseline characteristics of PPVI and surgical cohorts were analyzed to compare their 
demographic and clinical features. Demographic data included: age, gender, height, weight, and 
insurance status. Clinical data included: cardiac diagnosis, indication for pulmonary valve 
procedure, pre-operative factors, and other comorbidities. Echocardiographic and MRI data were 
also obtained to compare right ventricular ejection fraction (RVEF), degree of tricuspid 
regurgitation, right ventricular outflow tract maximum instantaneous gradient (RVOT MIG) and 
right ventricular end diastolic volume (RVEDV). Two-tailed t-tests and two-proportion z-tests 
were used to identify any statistically significant differences in demographic and clinical features 
between the PPVI and surgery groups. 
Cost Analysis 
This analysis examines cost only, because there is insufficient clinical data to conduct a 
cost-effectiveness analysis. The overall total costs was broken down into direct and indirect 
hospital costs, inpatient, and outpatient follow-up costs. There was no discounting necessary in 
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this analysis, because discounting is necessary for projection of future costs, but we only 
analyzed costs incurred in the past. 
Annual inflation rates specific for medical services were obtained from the US Bureau of 
Labor Statistics for the years 2007 to 2014. The annual rates were then compounded to convert 
costs from 2007-2013 to 2014 dollars. All costs are analyzed in 2014 dollars. 
Table 6: Annual inflation rate of medical services (22).  
Year Inflation Rate 
2007-2008 3.7% 
2008-2009 3.2% 
2009-2010 3.4% 
2010-2011 3.0% 
2011-2012 3.2% 
2012-2013 2.0% 
2013-2014 3.0% 
 
The cost analyses examined the direct and indirect costs associated with the valve 
procedure, including the associated hospitalization, any hospital readmissions, and outpatient 
follow-up visits within one month of discharge. The direct costs were further broken down by 
department to identify sources of variation. Multivariate regression analyses were conducted to 
identify any statistically significant differences in the total costs between the PPVI and surgical 
groups, as well as any demographic or clinical characteristics that affect the overall total cost. 
Similar analyses were also conducted to look for patient characteristics that affect variations in 
cost within each group. All statistical analyses were performed using STATA 12.1.  
Limitations of the Study 
This study is limited to hospital healthcare costs and does not include other costs to 
society, such as patient lost wages or home nursing services. In addition, the study is limited to 
the costs incurred during the procedure and follow-up costs in the one month after discharge. We 
did not predict costs over a long term time horizon.  
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The study is also limited by the quality of the financial data we were able to obtain. When 
we began analyzing the hospital detailed charges, we noticed that there were many errors. For 
example, some patients were missing charges for services like anesthesia, which were required 
for every procedure. In addition, the indirect costs were not further broken down. Lastly, we 
were unable to obtain actual physician fees, so standard Medicare reimbursements were used. 
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Results 
Patient Demographics  
The cohorts of PPVI and surgery patients had similar demographics, with no statistically 
significant differences in their gender, age, weight or height (Table 7). The PPVI cohort had 
slightly lower percentage of males (51%) than the surgery group (65%). The patient ages ranged 
from 4 to 56 years old. They had similar types of insurance coverage, with private insurance and 
Medicaid combining to cover more than 90% of both cohorts (Table 8). 
Table 7. Demographics. 
Demographics   PPVI (n = 47) Surgery (n = 51) P-value 
Male  51% 65% 0.175 
Age (years) Mean ± SD 22.2 ± 13.2 21.6 ± 14.3 0.834 
 Range 4.7 - 55.3 4.0 - 56.8  
Height (cm) Mean ± SD 152.4 ± 20.8 150.7 ± 27.2 0.719 
 Range 107.0 - 183.0 46.6 - 185.4  
Weight (kg) Mean ± SD 59.2 ± 29.2 53.2 ± 25.0 0.268 
 Range 18.0 - 161.2 15.4 - 106.0  
 
Table 8. Insurance status.  
Insurance PPVI (n = 47) Surgery (n = 49) P-value 
Private 48.9% 57.1% 0.426 
Medicare 2.1% 4.1% 0.587 
Medicaid 46.8% 38.8% 0.432 
State1 6.4% 4.1% 0.616 
None 2.1% 2.0% 0.977 
1 State refers to Connecticut state-sponsored insurance, which is not Medicare or Medicaid, for 
government employees. 
Clinical Characteristics  
There are three indications for pulmonary valve replacement: pulmonary insufficiency, 
pulmonary stenosis, and the combination of both conditions. In the PPVI group, the patients 
were roughly evenly split across the three indications. In contrast, 86% of surgical patients had 
pulmonary insufficiency (Table 9). 
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Table 9. Indication for pulmonary valve replacement or implantation. 
Indication PPVI (n = 47) Surgery (n = 51) P-value 
Pulmonary insufficiency (PI) 31.9% 86.3% < 0.001 
Pulmonary stenosis (PS) 34.0% 7.8% 0.001 
PI and PS 34.0% 5.9% <0.001 
 
Tetralogy of Fallot was the most common cardiac condition in the PPVI (46.8%) and 
surgical group (58.8%). However, the PPVI group had a high proportion of patients with 
pulmonary atresia with VSD (27.7%) and aortic stenosis (13.5%), while the surgical cohort had a 
high proportion of patients with pulmonary stenosis (23.5%).  
Table 10. Cardiac diagnosis. 
Diagnosis PPVI (n = 47) Surgery (n = 51) 
Aortic Stenosis 13.5% 0.0% 
DORV 4.3% 3.9% 
DTGA 4.3% 0.0% 
LTGA 2.1% 0.0% 
PA/IVS 0.0% 10.2% 
PA/VSD 27.7% 3.9% 
Pulmonary Stenosis 0.0% 23.5% 
TOF 46.8% 58.8% 
Truncus Arteriosis 4.3% 0.0% 
Abbreviations: DORV Double Outlet Right Ventricle, DTGA Dextro-Transposition of the Great 
Arteries, LTGA Levo-Transposition of the Great Arteries, PA/IVS Pulmonary Atresia with Intact 
Ventricular Septum, PA/VSD Pulmonary Atresia with Ventricular Septal Defect, TOF Tetralogy of 
Fallot 
 
Prior to the pulmonary valve replacement procedure, patients were evaluated for degree 
of tricuspid regurgitation and right ventricular outflow tract maximum instantaneous gradient 
(RVOT MIG) by echocardiography, and right ventricular end diastolic volume (RVEDV) and 
right ventricular ejection fraction (RVEF) by MRI. While all patients had echocardiography data, 
only 91 patients had reports that explicitly stated the parameters we compared. MRI data was 
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limited to 68 patients, because patients with pacemakers cannot undergo MRIs, and some 
patients had MRIs in other healthcare facilities, where medical records were not accessible to us. 
There were no statistically significant differences in the right ventricular ejection fraction 
and degree of tricuspid regurgitation between the two groups. Most patients had trivial to mild 
tricuspid regurgitation and an average right ventricular ejection fraction of 43-44% (Table 11). 
There were statistically significant differences in the RVOT MIG and RVEDV. RVOT MIG was 
greater in the PPVI group (51.1 ± 21.8 mmHg) than in the surgery group (27.6 ± 23.4 mmHg), 
while RVEDV was greater in the surgical group (170.3 ± 59.1 cc) than in the PPVI group (127.5 
± 42.1 cc).  
Table 11. Right ventricle disease characteristics. 
Degree of TR PPVI (n = 41) Surgery (n = 50) P-value 
None 0.049 0 0.117 
Trivial 0.341 0.38 0.707 
Mild 0.488 0.44 0.653 
Moderate 0.122 0.18 0.451 
    
RVOT MIG PPVI (n = 41) Surgery (n = 41) P-value 
Mean ± SD 51.1 ± 21.8 27.6 ± 23.4 < 0.001 
Range 13 - 120 6 - 100  
    
RVEF PPVI (n = 28) Surgery (n = 40) P-value 
Mean ± SD 44.1% ± 10.5% 43.2% ± 9.0% 0.712 
Range 27.0% - 72.0% 24.0% - 63%  
    
RVEDV PPVI (n = 28) Surgery (n = 41) P-value 
Mean ± SD 127.5 ± 42.1 170.3 ± 59.1 0.002 
Range 71.2 - 278.2 49.6 - 472.8  
 
Of the three main types of right ventricular outflow tracts, the majority of surgical 
patients had transannular patches. In contrast, PPVI patients had a nearly even split between 
bioprosthetic valve, homograft, and transannular patch. 
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Table 12. Type of pre-existing right ventricular outflow tract. 
 RVOT Type PPVI (n = 47) Surgery (n = 51) 
Bioprosthesis 17 1 
Homograft 17 7 
Transannular Patch 11 37 
Other  21 62 
1 1 Hancock, 1 REV. 2 4 valvotomy, 1 valvectomy, 1 valvuloplasty. 
A small number of patients in both cohorts had other conditions, with Noonan Syndrome 
and DiGeorge Syndrome being the most common (Table 13). A shared feature of these 
syndromes is cardiac defects, including pulmonary stenosis in Noonan Syndrome and tetralogy 
of Fallot in DiGeorge Syndrome.  
Table 13. Coexisting conditions. 
Condition Number of Patients 
  PPVI Surgery 
Noonan Syndrome 0 5 
DiGeorge Syndrome 3 0 
Down Syndrome 2 0 
Diabetes 1 2 
Hypercoagulability Disorder 1 0 
Hypocoagulability Disorder 2 0 
 
Hospital Admission 
There were statistically significant differences in the total length of hospital stay and 
length of Intensive Care Unit (ICU) stay. On average, surgery patients had ICU and overall 
hospital stays that were 2 and 3 days longer, respectively, than PPVI patients. PPVI patients 
rarely stayed in the ICU (Table 14). 
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Table 14. Length of hospital and ICU stay. 
Admission   PPVI (n = 47) Surgery (n = 51) P-value 
LOS (days) Mean ± SD 1.2 ± 0.7 4.3 ± 2.4 < 0.001 
  Median 1 4   
 Range 1 - 5 2 - 16  
ICU stay (days) Mean ± SD 0.3 ± 0.5 2.5 ± 1.2 < 0.001 
 Median 0 2  
  Range 0 - 2 1 - 7    
Surgical replacements were performed by five surgeons: Drs. Gary Kopf, Paul Kirshbom, 
Toshiharu Shinoka, Richard Kim, and Mohsen Karimi; they each performed 22, 17, 9, 2, and 1 
case(s), respectively. 
All PPVI procedures were performed by Dr. Jeremy Asnes. The access site for almost all 
patients was the right femoral vein (Table 15). 
Table 15. PPVI access site. 
Access Site Number of Patients 
Right Femoral 35 
Left femoral 8 
Right Jugular 3 
Transthoracic 1 
 
Eight PPVI patients experienced either arrhythmia or bleeding as post-procedural 
complications (Table 16). Ten surgery patients experienced complications that varied in severity, 
from bleeding and wound dehiscence to hypertensive crisis and pericardial effusion (Table 17).  
Table 16. PPVI complications. 
Number of Patients  PPVI Complication 
2 Arrhythmia 
6 Bleeding 
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Table 17. Surgical complications. 
Patient Surgical Complication 
1 Arrhythmia, pneumothorax 
2 Pericardial effusion requiring drainage 
3 Systemic vein obstruction 
4 Postoperative respiratory insufficiency requiring reintubation, pneumothorax, 
bleeding requiring reoperation 
5 Arrhythmia requiring electrical cardioversion or defibrillation 
6 Wound dehiscence 
7 Cardiac dysfunction resulting in low cardiac output 
8 Arrhythmia requiring drug therapy 
9 Pulmonary hypertensive crisis (PA pressure > systemic pressure), pneumonia 
10 Pneumothorax 
Cost Analysis 
There were statistically significant differences in the overall total, indirect, and outpatient 
follow-up costs between the PPVI and surgical group. The average overall total costs for PPVI 
and surgery patients were $71,966 and $90,917, respectively (p < 0.001). The indirect costs were 
$24,553 and $36,195 for the PPVI and surgical groups, respectively (p < 0.001). The direct costs 
were $46,850 and $55,756 for the PPVI and surgical groups, respectively (p = 0.008). Post-
procedure readmission costs were also higher in the surgical group, but this difference did not 
meet statistical significance (p = 0.889).  
The overall total cost is the sum of the direct and indirect hospital costs incurred during 
the admission, and the subsequent readmission and outpatient follow-up costs. The direct cost is 
composed of the detailed charges and physician fees from patients’ hospital admissions; these 
detailed charges were assorted into 16 categories to compare the differences in cost for the two 
cohorts with greater granularity. The 16 categories include procedure costs, ICU and non-ICU 
care, and ancillary services, like laboratory and pharmacy.  
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Table 18. Cost analysis. 
      PPVI (n = 47)   Surgery (n = 51)   Difference P-value 
Direct Cost        
 Mean ± SD $ 46,850 ± 11,630 $ 55,756 ± 19,365 $ 8,906 0.008 
 Range $ 21,577 - 77,012 $ 31,156 ± 137,634    
Indirect Cost        
 Mean ± SD $ 24,553 ± 7,018 $ 36,195 ± 15,735 $ 11,642 < 0.001 
 Range $ 9,327 -  45,174 $ 16,311 - 124,420    
Readmission Cost        
 Mean ± SD $ 267 ± 2,033 $ 354 ± 2,018 $ 58 0.889 
 Range $ 0 – 13,935 $ 0 - 13,883    
Outpatient Follow-up        
 Mean ± SD $ 267 ± 352  $ 418 ± 320 $ 151 0.029 
 Range $ 0 – 1,512 $ 0 – 1,063    
Overall Total Cost        
 Mean ± SD $ 71,966 ± 16,326 $ 90,917 ± 22,639 $ 18,951 < 0.001 
 Range $ 31,995 - 118,209 $ 60,441 - 172,688    
  
Of note, the category of cardiac lab includes all direct medical costs incurred during the 
PPVI procedure, excluding the physician fee, Melody valve, and its delivery system. Similarly, 
the operating room category includes all medical costs incurred during the pulmonary valve 
replacement surgery, excluding the physician fee and pulmonary valve implant. Not all patients 
used services from all categories – for example, no PPVI patients utilized rehabilitation services 
- so two average costs for each category were calculated: the average cost across only those 
patients that utilized the services, and the average cost across all patients of each cohort.  
There are several cost differences that are of note. Looking at averages across all patients, 
the costs in nearly all categories were higher for surgical patients compared to PPVI patients. 
Cardiac lab cost was $9,473, compared to $10,736 for the operating room. The total cost of ICU 
care was 14 times higher for surgical patients ($9,409) than for PPVI patients ($659). Non-ICU 
care for surgical patients ($2,794) was almost 2.6 times as expensive as that for PPVI patients 
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($1056). This pattern holds true for less costly departments as well, from diagnostic radiology 
($1,325 vs. $278) to respiratory care ($502 vs. $66). 
The notable exception to the trend of higher surgery costs is the pulmonary valve cost. 
The Melody valve and delivery system cost $26,154, which is 3.5 times the cost of the surgical 
valve ($7,556). 
The higher cost of the PPVI valve becomes pronounced when we compare the largest 
slices of the cost pie for the two groups. The Melody valve and delivery system accounts for 
36.3% of the overall total PPVI cost, compared to just 8.2% of the overall total cost that the 
surgical valve makes up. Cardiac lab cost is also a higher proportion of the PPVI overall total 
cost (15.2%) than the operating room is of the surgery overall total cost (11.7%). The indirect 
cost for PPVI ($24,553) is much lower than that for surgery ($36,195), but it makes up about the 
same percentage of the total cost, 34.1% and 39.4%, respectively.  The four categories, cardiac 
catheterization lab, pulmonary valve, physician fees, and indirect cost, account for more than 
95% of the total cost for PPVI. In contrast, the cost of surgery is spread across many more 
categories of services. 
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Figure 3. Average cost across all patients 
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Figure 4. Average cost across service-utilizing patients. 
 
$1,116 
$9,473 
$772 
$278 $7 
$2,582 
$24,553 
$13,935 
$323 
$1,460 
$0 $432 $0 $128 
$8,500 
$26,154 
$416 
$119 $48 
$3,143 
$0
$5,565 
$1,325 
$49 
$9,409 
$36,195 
$9,020 
$1,596 $3,239 
$10,736 
$418 $373 $872 
$10,824 
$7,556 
$256 
$711 $479 
 $-
 $5,000
 $10,000
 $15,000
 $20,000
 $25,000
 $30,000
 $35,000
 $40,000
C
o
st
 (
$
)
Department
PPVI
Surgery
33 
 
Figure 5. PPVI cost breakdown. 
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Figure 6. Surgery cost breakdown. 
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Multivariate Regression Analyses of Cost  
Multivariate regression analyses of the total cost was conducted to identify demographic 
and clinical characteristics that create variations in cost. The following variables were regressed 
against the total cost: procedure (PPVI vs. surgery), age, gender, height, weight, year, length of 
stay, ICU stay, insurance, indication for pulmonary valve replacement, cardiac diagnosis, degree 
of tricuspid regurgitation, RVOT MIG, RVEF, and RV EDV.  
The only variables that yielded statistically significant results when regressed 
individually with total cost were procedure type, year, total length of hospital stay, and ICU stay. 
However, ICU stay lost its significance when regressed with total length of stay, due to the high 
collinearity between them (r = 0.57); length of stay remained statistically significant. Procedure 
type also lost statistical significance when regressed with total length of stay due to collinearity 
(r =0.66). Lastly, year of procedure lost statistical significance when run with length of stay.  
One regression model we built controls for the baseline characteristics (age, gender, year, 
height, weight) to see if the clinical characteristics of procedure, length of stay, ICU stay, 
indication, RVEF, and RVEDV can account for any statistically significant difference in cost. 
The only variable that remained statistically significant was length of stay (Table 19). Based on 
the coefficient of the length of stay variable, the model tells us that each additional day of 
hospital stay increases cost by $4,498.50. This regression model accounts for 31.2% of the 
variation in overall total cost. 
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Table 19. Total cost regression model. 
Variable Coefficient Std. Error t P > t β 
Procedure 6978.26 10141.57 0.69 0.494 0.152 
Age 82.04 337.68 0.24 0.809 0.047 
Gender 1644.60 5923.51 0.28 0.782 0.036 
Year 1180.76 1565.77 0.75 0.454 0.108 
Height 175.70 207.45 0.85 0.401 0.171 
Weight -61.87 172.62 -0.36 0.721 -0.074 
ICU -564.21 3604.39 -0.16 0.876 -0.036 
LOS 4498.50 1808.55 2.49 0.016 0.505 
PI 1378.80 8678.28 0.16 0.874 0.029 
PS 2876.40 9422.76 0.31 0.761 0.045 
RVEF -42.02 675.52 -0.06 0.951 -0.008 
RVEDV -16.81 36.82 -0.46 0.65 -0.062 
Constant -2331844.00 3152572.00 -0.74 0.463  
R2  =  0.312     
Adjusted R2 =  0.162         
 
We conducted a similar analysis of the total costs for the PPVI and surgery patients 
individually. For the PPVI group, none of the variables listed in Table 19 maintained statistical 
significance when run together. Instead, the strongest regression model consisted of the 
procedure indication of pulmonary insufficiency, but did not have high R2. This model suggests 
that, compared to the indication of pulmonary insufficiency, versus pulmonary stenosis or 
pulmonary stenosis with insufficiency, the cost decreases by $11,303. 
Table 20. PPVI total cost regression model. 
Variable Coefficient Std. Error t P > t β 
PI -11303.15    4882.58     -2.31    0.025 -0.326 
Constant                 75573.08 2758.33 27.40 0.000  
R2  = 0.106     
Adjusted R2 = 0.087     
 
Finally, the regression of costs for surgical patients yielded statistical significance with 
the variables, length of stay and moderate tricuspid regurgitation. To see if there is a correlation 
37 
 
between length of stay and tricuspid regurgitation, a scatter plot of the two variables was created. 
There was no correlation found between these two variables (Figure 7). Of note, regression of 
total cost with the different surgeons was not statistically significant.  
Table 21. Surgery total cost regression model. 
Variable Coefficient Std. Error t P > t β 
LOS 4677.08 1163.87 4.02 < 0.001 0.496 
Moderate TR 14296.82 7213.88 1.98 0.053 0.24 
Constant 68341.87 6001.04 11.39 < 0.001  
R2 =  0.2884         
Adjusted R2 =  0.2581         
 
Figure 7.  Scatter plot of length of hospital stay vs. degree of tricuspid regurgitation. 
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Discussion 
Patient Demographics 
The two patient groups had similar demographics, which assured us that age, gender, 
height, and weight differences would be unlikely confounding factors in the cost analysis. 
Otherwise, if one cohort had a higher proportion of older patients who have more comorbidities, 
for example, age differences may lengthen their recovery time and hospital stay, which would 
skew that group to have higher costs.  
Insurance coverage was also analyzed, because healthcare providers typically receive 
lower reimbursements from government-sponsored insurance than from private entities. The 
costs we obtained were derived by multiplying charges on patient invoices by cost-to-charge 
ratios, and patients with private insurance are charged higher rates. Thus, having similar 
assortments of insurance types in the two cohorts decreased the likelihood that insurance type 
would be a confounding factor.  
Clinical Characteristics  
There were significantly more surgery patients who had pulmonary insufficiency as their 
indication for valve replacement. This is because pulmonary stenosis is not frequently an 
indication for surgery. Prior to the introduction of the PPVI, patients with pulmonary stenosis 
could have their right ventricular outflow tract dilated in the catheter lab, rather than undergo 
surgery. Furthermore, patients with severe pulmonary insufficiency were more likely to have 
transannular patches and large RVOTs that would render them ineligible for the Melody valve.  
There were more patients with pulmonary stenosis in the PPVI group: patients who 
would have undergone RVOT dilation in the catheter lab in the past, were now able to have a 
RVOT implanted via PPVI. 
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Nearly all surgical patients had free pulmonary insufficiency on cardiac 
echocardiography. Greater severity of pulmonary insufficiency results in right ventricular 
dilation, which accounts for the higher RVEDV in surgical patients (170.3 ± 59.1 cc) than in the 
PPVI group (127.5 ± 42.1 cc) that was statistically significant (p = 0.002).   
Conversely, pulmonary stenosis drives up RVOT pressure, which explains the 
statistically significant difference in RVOT MIG between the two groups. In the PPVI group, 
68% of the patients had pulmonary stenosis (the sum of patients with pulmonary stenosis only 
and those with both pulmonary stenosis and pulmonary insufficiency) compared to only 13.7% 
in the surgery group. As such, the average RVOT MIG in the PPVI cohort (51.1 ± 21.8 mmHg) 
was nearly twice that of the surgery cohort (27.6 ± 23.4 mmHg, p = 0.000). 
The right ventricular ejection fraction can be considered a surrogate marker for right 
ventricular function. Tricuspid valve regurgitation may adversely affect venous hemodynamics 
and lead to venous and organ dysfunction. Since there were no statistically significant 
differences in these measures, right ventricular systolic function and tricuspid function in the two 
groups are similar. In other words, the surgery group did not have more severe cardiac disease 
that could lengthen hospital recovery time. 
Hospital Admission 
The ICU and total length of stay were significantly higher in the surgery group. This is 
understandable, considering open thoracic surgery is more traumatic than minimally-invasive 
transcatheter procedures. The longer recovery time and more severe complications in the surgery 
group thus account for the longer hospital stays.  
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Cost Analysis 
The overall total cost associated with surgery was $18,951 higher than that with PPVI. 
This difference is largely due to the $11,642 difference in indirect cost. The indirect cost 
includes the non-medical hospital costs that are associated with providing care, such as 
administration, finance, utilities, security, etc. Indirect costs were not broken down into detailed 
charges in the same way that direct costs were. Instead, they are a proportion of the direct cost.  
What determines the exact magnitude of the indirect cost is nebulous: as one staff 
member of the YNHH Financial Planning and Budget office described, “The indirect costs are a 
bit of a mix of art and science.” In general, indirect costs are higher for departments that have 
higher capital costs. For example, operating rooms have high capital costs associated with the 
maintenance of space, equipment, utilities, etc. As such, operating rooms have higher indirect 
costs than cardiac labs do.  
The second largest source of the cost difference, $8,906, is the direct healthcare cost. As 
noted in the results section, the average cost of nearly every category was higher for surgery than 
for PPVI patients. For example, the care for both ICU and non-ICU were several fold higher for 
surgery than PPVI patients. Inpatient hospital care accounts for just 2.4% of the total cost for the 
PPVI group, compared to 13.2% in the surgery group. However, this is because surgery patients 
have longer hospital and ICU stays, not because they are charged more per day. This is 
elucidated when we compare the average costs distributed across only the utilizing patients: the 
average ICU cost for the surgery patients is 3.6 times that of the average cost for PPVI patients. 
However, surgical patients tended to stay in the ICU for 2-3 days longer than PPVI patients, 
which means the ICU cost per day is nearly equivalent for the two groups.   
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Because the overall total cost is lower for PPVI patients, the relatively more expensive 
valve ($26,154 vs. $7,556) makes up a much larger component of the total cost: 36.3% in PPVI 
versus 8.2% in surgery group.  
We can sum up all the average costs associated directly with the pulmonary valve 
procedure to derive the total procedure cost (sum of cardiac lab or operating room, physician fee, 
valve, cardioperfusionist, and anesthesia): the average total procedure cost is $44,224 for PPVI 
and $38,040 for surgery. The percentage of the overall total cost that the procedure accounts for, 
is lower in surgery (41.2%) than PPVI (61.5%). 
Smaller categories of cost are also higher for surgery patients because longer hospital 
stays require more services – more medications, laboratory tests, supplies, respiratory care, etc.  
We did not analyze other costs to society here, such as patient lost wages. Patients are 
typically recommended to take three weeks for recovery time after surgery and one week after 
PPVI, so inclusion of this cost would have increased the cost gap between the two groups.  
In published economic analyses, the higher overall total cost associated with PPVI has 
been attributed to the higher cost of the transcatheter valve. It was stated that PPVI will 
eventually become more economical once the cost of the valve decreases. However, we see that 
in YNHH, the cost of PPVI is already lower than surgery. When the cost of the transcatheter 
valve decreases in the future, the cost differential between PPVI and surgery will continue to 
increase at YNHH. 
Multivariate Regression Analyses of Cost  
The strongest regression model for the overall total cost found that the length of stay was 
the only statistically significant variable that explains variation in cost. As discussed in the cost 
analyses above, longer lengths of stay result in higher costs due to higher usage of hospital 
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resources (eg. supplies and medications) and services (eg. nursing and respiratory care). It is also 
important to note that none of the demographic or clinical characteristics of the cohorts had 
statistically significant associations with cost. In other words, patient age, indication for 
pulmonary valve replacement, and cardiac diagnosis have little effect on the overall total cost. 
What matters most is how long a patient stays in the hospital. 
When examining the factors that affect cost among PPVI patients, it is noteworthy that 
the indication of pulmonary insufficiency was the only statistically significant variable identified 
and decreases cost. This may be because patients with pulmonary stenosis tend to have multiple 
angioplasties and multiple stents placed prior to PPVI. As a result, patients with pulmonary 
insufficiency, who have fewer RVOT treatments before PPVI, incur lower costs. 
In the regression model for the overall total cost for surgery, length of stay and moderate 
tricuspid regurgitation were the statistically significant variables affecting cost. The length of 
stay is an understandable predictor of cost. More severe tricuspid regurgitation is an indicator of 
poorer tricuspid function, which we hypothesized may increase recovery time and therefore, 
length of stay. However, the scatter plot of length of stay versus tricuspid regurgitation showed 
no correlation between the two variables, so it is unclear how moderate tricuspid regurgitation 
increases cost. 
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Conclusions 
This study found that surgery is more costly than PPVI, because surgery is associated 
with longer ICU and hospital stays due to the trauma of open thoracic surgery. The largest 
component of total overall cost for both groups was the indirect cost, consisting of 34.1% and 
39.4% of the total for PPVI and surgery, respectively. Surgery costs were higher in every 
category except for the pulmonary valve. The multivariate regression analyses of demographic 
and clinical characteristics yielded length of hospital stay as the only statistically significant 
predictor of cost. 
Economic analyses in healthcare are increasingly important in this era of rising costs. In 
the future, if PPVI and surgical replacement are found to be clinically equally effective and PPVI 
is shown to be consistently more economical, healthcare payers may choose to only pay for PPVI 
when patients are eligible for both procedures – as they have already done with numerous other 
treatment options. Future economic studies comparing PPVI and surgery should include larger 
populations and examine cost-effectiveness, once there are sufficiently large patient populations 
who have had transcatheter pulmonary valves for longer periods of time to compare their relative 
clinical effectiveness. 
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